RESPIRI LIMITEDRR

RESPIRI LIMITED

0.038AUDD
−0.001−2.56%
Last update at Mar 31, 05:11 GMT
AUD
No trades
See on Supercharts

RSH fundamentals

Key facts

Market capitalization‪61.44 M‬AUD
Basic EPS (TTM)−0.01AUD
Founded1987
CEOMarjan Mikel
Websiterespiri.co
About

Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. Its proprietary apps, software, and devices will help people monitor the symptoms of their conditions, increase their awareness of risk of attack, adhere to their medication plans, improve outcomes, and reduce healthcare expenditures. The firm operates through the Australia and Israel segments. The Australia segment includes research, development, and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment refers to the research, development and, commercialization of medical devices, and the production of mobile health applications in Israel. The company was founded by Noam Gavriely in 1987 and is headquartered in Melbourne, Australia.

Ownership
‪‪1.58 B‬‬
Free Float shares
‪‪1.40 B‬‬ (88.81%)
Closely held shares
‪‪176.31 M‬‬ (11.19%)
Free Float shares
‪‪1.40 B‬‬ (88.81%)
Closely held shares
‪‪176.31 M‬‬ (11.19%)
Capital structure
Market cap
‪‪61.44 M‬‬
Debt
‪‪87.37 K‬‬
Cash & equivalents
‪‪1.25 M‬‬
Enterprise value
‪‪60.27 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪61.44 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
38.37x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
38.37x
Valuation ratios
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪120.00‬
‪240.00‬
‪360.00‬
‪480.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−28,350.00%‬
‪−21,350.00%‬
‪−14,350.00%‬
‪−7,350.00%‬
‪−350.00%‬
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪‪−4.50 M‬‬
‪‪−3.00 M‬‬
‪‪−1.50 M‬‬
‪0.00‬
‪‪1.50 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−4.50 M‬‬
‪‪−3.00 M‬‬
‪‪−1.50 M‬‬
‪0.00‬
‪‪1.50 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−3.90 M‬‬
‪‪−2.60 M‬‬
‪‪−1.30 M‬‬
‪0.00‬
‪‪1.30 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Medical Devices
By country
Period: 2024
United States
Australia

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '23
H1 '24
H2 '24
H1 '25
H2 '25
‪0.00‬
‪‪250.00 K‬‬
‪‪500.00 K‬‬
‪‪750.00 K‬‬
‪‪1.00 M‬‬
Actual
Earnings
Next:Sep 2, 2025
H1 '23
H1 '24
H2 '24
H1 '25
H2 '25
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
Actual

Dividends

Dividend yield, history and sustainability

RSH does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪‪−4.50 M‬‬
‪‪−3.00 M‬‬
‪‪−1.50 M‬‬
‪0.00‬
‪‪1.50 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.30 M‬‬
‪‪2.60 M‬‬
‪‪3.90 M‬‬
‪‪5.20 M‬‬
Assets
Liabilities